Regulus Therapeutics Inc.
RGLS
Pozycja w akcjach
#17341
Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development... Regulus Therapeutics Inc., a biopharmaceutical firm in its clinical development phase, is dedicated to uncovering and advancing novel medications. Based in San Diego, California, the company's core focus is on modulating microRNAs to combat a variety of diseases across the United States. Its current pipeline highlights RG-012, an anti-miR compound engineered to inhibit miR-21, which is currently in a Phase II clinical study for Alport syndrome, a severe renal condition. Another significant candidate, RGLS8429, an anti-miR agent targeting miR-17, is being evaluated in a Phase 1b clinical trial for autosomal dominant polycystic kidney disease. Beyond these clinical programs, Regulus is also cultivating an extensive preclinical portfolio, emphasizing drug candidates with precise, organ-selective delivery strategies. The company was established in 2007.
Cena akcji
$8.16
Ostatnia synchronizacja: 2025-06-26
Kapitalizacja rynkowa
$234.57M
Zmiana (1 dzień)
0.00%
Zmiana (1 rok)
-56.96%
Kraj
US
Handel Regulus Therapeutics Inc. (RGLS)
Kategoria
Healthcare
EPS dla Regulus Therapeutics Inc. (RGLS)
EPS na dzień March 2024 TTM: $-3.43
Według najnowszych raportów finansowych i ceny akcji firmy Regulus Therapeutics Inc., obecny EPS (TTM) wynosi $-3.43. Na koniec roku 2022 firma miała EPS w wysokości $-1.18, spadek w porównaniu do do EPS z roku 2021, który wynosił $-4.38.
Historia EPS dla Regulus Therapeutics Inc. od 2002 do 2026
EPS na koniec każdego roku
| Rok | EPS | Zmień |
|---|---|---|
| 2026 (TTM) | $-3.43 | 124.20% |
| 2023 | $-1.53 | 29.29% |
| 2022 | $-1.18 | -73.05% |
| 2021 | $-4.38 | -579.31% |
| 2020 | $0.91 | -200.51% |
| 2019 | $-0.91 | 75.75% |
| 2018 | $-0.52 | -28.17% |
| 2017 | $-0.72 | 20.04% |
| 2016 | $-0.60 | -494.54% |
| 2015 | $0.15 | -518.73% |
| 2014 | $-0.04 | -135.21% |
| 2013 | $0.10 | 212.42% |
| 2012 | $0.03 | 13.40% |
| 2011 | $0.03 | -12.87% |
| 2010 | $0.03 | -6.70% |
| 2009 | $0.04 | -31.55% |
| 2008 | $0.05 | 2.15% |
| 2007 | $0.05 | 100.78% |
| 2006 | $0.03 | 23.19% |
| 2005 | $0.02 | 1,280.00% |
| 2004 | 0.00 | -105.98% |
| 2003 | $-0.03 | -81.60% |
| 2002 | $-0.14 | 0.00% |
EPS dla podobnych firm lub konkurentów
| Firma | EPS | Różnica w EPS | Kraj |
|---|---|---|---|
| $17.32 | -604.93% |
US
|
|
| $-7.98 | 132.64% |
US
|
|
| $-5.29 | 54.22% |
AU
|
|
| - | - |
CH
|
|
| $27.74 | -908.70% |
NL
|
